🔗 Share this article

While the United States undertakes historic adjustments to its vaccination guidelines, an unexpected name has emerged somewhat surprisingly: Høeg, a Danish American sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccinations during the global health crisis and has concentrated on possible fatalities following Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Childhood Vaccine Schedule

Public health authorities were set to announce radical revisions to the childhood vaccination calendar in December, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US at odds with a large portion of the global community with no evidence for public health gain. The planned update has been delayed until the coming year.

Rather than the top vaccines chief, Høeg is listed to address the audience at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth person to run the center this calendar year.

Consolidating Power at the Agency

The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the FDA – and it signals a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for halting some childhood immunization guidelines in the US so as to align more in line with Denmark, a society with universal health coverage and a population approximately the population of the state of Wisconsin.

To date comments, she has kept her attention on immunizations – traditionally the purview of Dr. Prasad, director of the FDA’s vaccine center – rather than medication approval.

Concerns Over Expertise

Dr. Høeg has no obvious experience in pharmaceutical research, oversight or leadership, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the necessary background” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She is not versed in leading a major agency. She is not an expert in industry regulation.”

Former commissioners of the center would “understand laws and regulations and the science of medication creation”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that prior appointees who led CBER have had.”

This division has an immense range of responsibilities at the agency, the former commissioner stated.

“Many people just zeroes in on the new drug program, but the off-patent medication office authorizes thousands of generic medications. There’s a biologic copycat branch, over-the-counter program and more, and all of those need to be managed,” Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a substantial administrative component to the job, which manages over 5,000 employees. “It’s a huge administrative position, if you execute it properly,” she added.

Response and Contentious Policies

In response to concerns about Dr. Høeg's qualifications and whether this selection represents more teamwork among agency officials on immunizations, a representative stated that the “inquiries stem from inaccurate presumptions”.

“Her resume aligns with the responsibilities of her position,” the spokesperson stated, noting the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious expedited drug-approval program that reportedly troubled her former heads. “How are these therapies being chosen for this expedited pathway? Who is making the decisions?” Howard asked. “There’s a lot of confidentiality occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards more relaxed regulations of pharmaceuticals, aside from shots.”

Documented Past Work on Vaccines

With vaccines, Høeg has a more established, if troubling, history, some experts observe. She released a analysis using non-validated volunteer-provided data to determine the incidence of myocarditis following Covid vaccination. She counseled the Florida surgeon general Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the incoming administration encompassed changing guidelines for novel immunizations and discontinuing “optional” vaccines, she said post-election on a audio program. At the agency, Høeg has according to sources floated the idea of barring adolescent males from receiving COVID-19 vaccinations.

“She is an thorough ideologue who begins with her preconceived notions and tailors the evidence to accommodate the science in a highly deceptive, untruthful fashion,” Howard argued.

Consolidating Power and a “Push for Payback”

Høeg aligned with other contrarians, {like|